The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals

Journal of Medical Virology

Volumn 86, Issue 11, 2014, Pages 1990-1997

  Mimuro, Jun ^a   Mizukami, Hiroaki ^a   Shima, Midori ^b   Matsushita, Tadashi ^c   Taki, Masashi ^d   Muto, Shinji ^e   Higasa, Satoshi ^f   Sakai, Michio ^g   Ohmori, Tsukasa ^a   Madoiwa, Seiji ^a   Ozawa, Keiya ^a   Sakata, Yoichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d ST MARIANNA UNIVERSITY   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

AAV vector; Epidemiology; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; HEMOPHILIA; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MIDDLE AGED; SCHOOL CHILD; SEROTYPE; VIRUS CAPSID; YOUNG ADULT; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DEPENDOPARVOVIRUS; IMMUNOLOGY; JAPAN; PARVOVIRIDAE INFECTIONS; VIROLOGY;

ADULT; AGE FACTORS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CAPSID; DEPENDOVIRUS; HUMANS; JAPAN; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84944215188     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23818     Document Type: Article

References (32)

1. Asokan A, Schaffer DV, Samulski RJ. 2012. The AAV vector toolkit: Poised at the clinical crossroads. Mol Ther 20:699-708.
2. Bartel M, Schaffer D, Buning H. 2011. Enhancing the clinical potential of AAV vectors by capsid engineering to evade preexisting immunity. Front Microbiol 2:204.
3. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712.
4. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. 2009. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J Infect Dis 199:381-390.
5. Campagna M, Siddu A, Meloni A, Basciu C, Ferrai L, Pettinau A, Cardia C, Masia G, Coppola RC. 2012. Changing pattern of hepatitis a virus epidemiology in an area of high endemicity. Hepat Mon 12:382-385.
6. Chandler RJ, Venditti CP. 2011. A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates. Mol Ther 19:826-827.
7. Chuah MK, Nair N, VandenDriessche T. 2012. Recent progress in gene therapy for hemophilia. Hum Gene Ther 23:557-565.
8. Erles K, Sebokova P, Schlehofer JR. 1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59:406-411.
9. Foster H, Popplewell L, Dickson G. 2012. Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum Gene Ther 23:676-687.
10. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381-6388.
11. Gao G, Wang Q, Calcedo R, Mays L, Bell P, Wang L, Vandenberghe LH, Grant R, Sanmiguel J, Furth EE, Wilson JM. 2009. Adenoassociated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther 20:930-942.
12. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99:11854-11859.
13. Grieger JC, Samulski RJ. 2012. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 507:229-254.
14. High, K. 2007. Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2007:466-472.
15. Hufnagel RB, Ahmed ZM, Correa ZM, Sisk RA. 2012. Gene therapy for Leber congenital amaurosis: Advances and future directions. Graefes Arch Clin Exp Ophthalmol 250:1117-1128.
16. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, Zhou S, Scallan CD, Sommer J, Vijay S, Mingozzi F, High KA, Pierce GF. 2006. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108:3321-3328.
17. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:257-261.
18. Li C, Hirsch M, DiPrimio N, Asokan A, Goudy K, Tisch R, Samulski RJ. 2009. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol 83:6817-6824.
19. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE. 2012. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 19:288-294.
20. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972.
21. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347.
22. Mimuro J, Mizukami H, Hishikawa S, Ikemoto T, Ishiwata A, Sakata A, Ohmori T, Madoiwa S, Ono F, Ozawa K, Sakata Y. 2013. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther 21:318-323.
23. Mingozzi F, High KA. 2011. Immune responses to AAV in clinical trials. Curr Gene Ther 11:321-330.
24. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, Pierce GF, Ertl HC, High KA. 2007. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13:419-422.
25. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES, High KA. 2009. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114:2077-2086.
26. Mizukami H, Mimuro J, Ogura T, Okada T, Urabe M, Kume A, Sakata Y, Ozawa K. 2006. Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther 17:921-928.
27. Mohammadi ES, Ketner EA, Johns DC, Ketner G. 2004. Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line. Nucleic Acids Res 32:2652-2659.
28. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, Nakano I. 2010. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18:1731-1735.
29. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN, Tuddenham EG, Kemball-Cook G, McIntosh J, Boon-Spijker M, Mertens K, DavidoffAM. 2006. Self-complementary adenoassociated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107:2653-2661.
30. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, Nawathe S, Waddington SN, Bronson R, Jackson S, Donahue RE, High KA, Mingozzi F, Ng CY, Zhou J, Spence Y, McCarville MB, Valentine M, Allay J, Coleman J, Sleep S, Gray JT, Nienhuis AW, DavidoffAM. 2011a. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 19:876-885.
31. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, DavidoffAM. 2011b. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365:2357-2365.
32. Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, Hajjar RJ, Weber T. 2012. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 20:73-83.